Table 4 Laboratory findings of adult COVID-19 patients with different levels of HDL-C
|  | Normal range | Low HDL (n = 46) | High HDL (n = 182) | P value |
|---|---|---|---|---|
White blood cell count, ×109/L, median (IQR) | 4–10 | 4.78 (3.82, 6.13) | 4.58 (3.52, 5.66) | 0.627 |
Lymphocyte count, ×109/L, median (IQR) | 0.8–4.0 | 1.02 (0.72, 1.51) | 1.17 (0.84, 1.59) | 0.207 |
Lymphocyte %, median (IQR) | 20–40 | 22.35 (17.58, 30.10) | 27.45 (20.05, 33.00) | 0.050 |
Alanine aminotransferase, U/L, median (IQR) | 0–42 | 21.49 (16.13, 30.28) | 18.81 (13.81, 26.61) | 0.044 |
Aspartate aminotransferase, U/L, median (IQR) | 0–37 | 25.87 (19.53, 34.01) | 23.76 (19.25, 28.77) | 0.109 |
Total bilirubin, μmol/L, median (IQR) | 3.4–20.5 | 11.16 (8.16, 15.35) | 10.87 (8.68, 16.36) | 0.769 |
C-reactive protein, mg/L, median (IQR) | 0–8 | 27.83 (14.68, 44.74) | 12.56 (3.29, 26.88) | < 0.001 |
Erythrocyte sedimentation rate, mm/h, median (IQR) | 0–15 | 52.00 (22.00, 67.75) | 39.50 (22.0, 68.25) | 0.538 |
Procalcitonin, ≥0.05 ng/mL, No. (%) | < 0.05 | 17 (37.0%) | 46 (25.3%) | 0.113 |
Creatinine, μmol/L, median (IQR) | 21.5–104 | 53.70 (43.61, 65.02) | 50.85 (41.22, 64.02) | 0.209 |
Creatine kinase, U/L, median (IQR) | 10–190 | 83.35 (57.05, 148.63) | 69.75 (46.30, 114.45) | 0.116 |
Creatine kinase-MB, U/L, median (IQR) | 0–24 | 9.35 (5.33, 12.50) | 9.57 (6.40, 12.92) | 0.624 |